Randy J. Chandler
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Randy J. Chandler has a total of 214 co-authors. Here are the top co-authors by number of shared publications:
- Charles P. Venditti
National Human Genome Research Institute, National Institutes of Health Bethesda Maryland USA
29 shared publications Charles P. Venditti
Developmental Genomics Section, Translational and Functional Genomics Branch, National Human Genome Research Institute, Bethesda, MD, USA
5 shared publications- Nuria Carrillo-Carrasco
Organic Acid Research Section, Genetics and Molecular Biology Branch, National Human Genome Research Institute, National Institutes of Health, Building 49, Room 4A18, Bethesda, MD 20892, USA
5 shared publications - Irini Manoli
Medical Genomics and Metabolic Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland
4 shared publications - Alana L. Gibson
Department of Human Health and Services, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA
3 shared publications Jennifer L. Sloan
Organic Acid Research Section, Medical Genomics and Metabolic Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland
3 shared publications
Latest Publications
- Open Access
- 24 July 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (17)
Dissecting the effect of mitochondrial BCAT inhibition in methylmalonic acidemia
Methylmalonic acidemia (MMA) is a severe metabolic disorder affecting multiple organs because of a distal block in branched-chain amino acid (BCAA) catabolism. Standard of care is limited to protein restriction and supportive care during metabolic decompensation. Severe cases require liver/kidney transplantation, and there is a clear need for better therapy. Here, we investigated the effects of a small molecule branched-chain amino acid transaminase (BCAT) inhibitor in human MMA hepatocytes and an MMA mouse model. Mitochondrial BCAT is the first step in BCAA catabolism, and reduction of flux through an early enzymatic step is successfully used in other amino acid metabolic disorders. Metabolic flux analyses confirmed robust BCAT inhibition, with reduction of labeling of proximal and distal BCAA-derived metabolites in MMA hepatocytes. In vivo experiments verified the BCAT inhibition, but total levels of distal BCAA catabolite disease markers and clinical symptoms were not normalized, indicating contributions of substrates other than BCAA to these distal metabolite pools. Our study demonstrates the importance of understanding the underlying pathology of metabolic disorders for identification of therapeutic targets and the use of multiple, complementary models to evaluate them.
- 24 July 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (17)
Open AccessDissecting the effect of mitochondrial BCAT inhibition in methylmalonic acidemia
Methylmalonic acidemia (MMA) is a severe metabolic disorder affecting multiple organs because of a distal block in branched-chain amino acid (BCAA) catabolism. Standard of care is limited to protein restriction and supportive care during metabolic decompensation. Severe cases require liver/kidney transplantation, and there is a clear need for better therapy. Here, we investigated the effects of a small molecule branched-chain amino acid transaminase (BCAT) inhibitor in human MMA hepatocytes and an MMA mouse model. Mitochondrial BCAT is the first step in BCAA catabolism, and reduction of flux through an early enzymatic step is successfully used in other amino acid metabolic disorders. Metabolic flux analyses confirmed robust BCAT inhibition, with reduction of labeling of proximal and distal BCAA-derived metabolites in MMA hepatocytes. In vivo experiments verified the BCAT inhibition, but total levels of distal BCAA catabolite disease markers and clinical symptoms were not normalized, indicating contributions of substrates other than BCAA to these distal metabolite pools. Our study demonstrates the importance of understanding the underlying pathology of metabolic disorders for identification of therapeutic targets and the use of multiple, complementary models to evaluate them.
- Open Access
- 21 November 2024
- Published by Elsevier in Molecular Therapy - Methods & Clinical Development
- Vol. 32 (4) , 101373
Determining recombinant AAV capsid extracellular and intracellular biodistribution by dual radioisotope labeling
- 21 November 2024
- Published by Elsevier in Molecular Therapy - Methods & Clinical Development
- Vol. 32 (4) , 101373
Open AccessDetermining recombinant AAV capsid extracellular and intracellular biodistribution by dual radioisotope labeling
- 17 May 2024
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 207,p. e66809
Systemic Treatment for Postnatal, Juvenile, and Runted Adult Mice by Retrobulbar Sinus Injection
While tail vein injections are frequently used as a systemic route of delivery in adult mice, retrobulbar injections are an alternative method for systemic delivery with fewer limitations. First, tail vein injections (TVIs) are limited to adult mice where the size of the tail vein is suitable for access. Being restricted to treating adult mice can be problematic when dealing with mouse models that do not survive to adulthood. Second, TVIs are not feasible for mouse models with growth retardation phenotypes where the mice never achieve the size of adult wildtype mice. Therefore, retrobulbar injections can be successfully used to treat both young and small adult mice. Lastly, retrobulbar injections are performed under anesthesia, which is less stressful on the mice than TVIs that are commonly performed without anesthesia. This article presents a protocol and detailed instructions for retrobulbar injections that can be used for systemic delivery to small and young mice.
- 17 May 2024
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 207,p. e66809
Systemic Treatment for Postnatal, Juvenile, and Runted Adult Mice by Retrobulbar Sinus Injection
While tail vein injections are frequently used as a systemic route of delivery in adult mice, retrobulbar injections are an alternative method for systemic delivery with fewer limitations. First, tail vein injections (TVIs) are limited to adult mice where the size of the tail vein is suitable for access. Being restricted to treating adult mice can be problematic when dealing with mouse models that do not survive to adulthood. Second, TVIs are not feasible for mouse models with growth retardation phenotypes where the mice never achieve the size of adult wildtype mice. Therefore, retrobulbar injections can be successfully used to treat both young and small adult mice. Lastly, retrobulbar injections are performed under anesthesia, which is less stressful on the mice than TVIs that are commonly performed without anesthesia. This article presents a protocol and detailed instructions for retrobulbar injections that can be used for systemic delivery to small and young mice.
- 7 August 2023
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 47 (1) , 63-79
Gene therapy for organic acidemias: Lessons learned from methylmalonic and propionic acidemia
Organic acidemias (OA) are a group of rare autosomal recessive disorders of intermediary metabolism that result in a systemic elevation of organic acid. Despite optimal dietary and cofactor therapy, OA patients still suffer from potentially lethal metabolic instability and experience long‐term multisystemic complications. Severely affected patients can benefit from elective liver transplantation, which restores hepatic enzymatic activity, improves metabolic stability, and provides the theoretical basis for the pursuit of gene therapy as a new treatment for patients. Because of the poor outcomes reported in those with OA, especially methylmalonic and propionic acidemia, multiple gene therapy approaches have been explored in relevant animal models. Here, we review the results of gene therapy experiments performed using MMA and PA mouse models to illustrate experimental paradigms that could be applicable for all forms of OA.
- 7 August 2023
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 47 (1) , 63-79
Gene therapy for organic acidemias: Lessons learned from methylmalonic and propionic acidemia
Organic acidemias (OA) are a group of rare autosomal recessive disorders of intermediary metabolism that result in a systemic elevation of organic acid. Despite optimal dietary and cofactor therapy, OA patients still suffer from potentially lethal metabolic instability and experience long‐term multisystemic complications. Severely affected patients can benefit from elective liver transplantation, which restores hepatic enzymatic activity, improves metabolic stability, and provides the theoretical basis for the pursuit of gene therapy as a new treatment for patients. Because of the poor outcomes reported in those with OA, especially methylmalonic and propionic acidemia, multiple gene therapy approaches have been explored in relevant animal models. Here, we review the results of gene therapy experiments performed using MMA and PA mouse models to illustrate experimental paradigms that could be applicable for all forms of OA.
- Open Access
- 9 May 2023
- Published by Elsevier in Molecular Therapy - Methods & Clinical Development
- Vol. 29, 347-349
From Puppies to adults: In vivo editing of hepatocytes in a canine model of glycogen storage disease type Ia
- 9 May 2023
- Published by Elsevier in Molecular Therapy - Methods & Clinical Development
- Vol. 29, 347-349
Open AccessFrom Puppies to adults: In vivo editing of hepatocytes in a canine model of glycogen storage disease type Ia
- Open Access
- 11 November 2021
- Published by Elsevier in Molecular Therapy - Methods & Clinical Development
- Vol. 23, 619-632
In vivo genome editing at the albumin locus to treat methylmalonic acidemia
- 11 November 2021
- Published by Elsevier in Molecular Therapy - Methods & Clinical Development
- Vol. 23, 619-632
Open AccessIn vivo genome editing at the albumin locus to treat methylmalonic acidemia
- Open Access
- 18 August 2021
- Published by Life Science Alliance, LLC in Life Science Alliance
- Vol. 4 (10) , e202101040
Improved systemic AAV gene therapy with a neurotrophic capsid in Niemann–Pick disease type C1 mice
Niemann–Pick C1 disease (NPC1) is a rare, fatal neurodegenerative disease caused by mutations in NPC1, which encodes the lysosomal cholesterol transport protein NPC1. Disease pathology involves lysosomal accumulation of cholesterol and lipids, leading to neurological and visceral complications. Targeting the central nervous system (CNS) from systemic circulation complicates treatment of neurological diseases with gene transfer techniques. Selected and engineered capsids, for example, adeno-associated virus (AAV)-PHP.B facilitate peripheral-to-CNS transfer and hence greater CNS transduction than parental predecessors. We report that systemic delivery to Npc1m1N/m1N mice using an AAV-PHP.B vector ubiquitously expressing NPC1 led to greater disease amelioration than an otherwise identical AAV9 vector. In addition, viral copy number and biodistribution of GFP-expressing reporters showed that AAV-PHP.B achieved more efficient, albeit variable, CNS transduction than AAV9 in Npc1m1N/m1N mice. This variability was associated with segregation of two alleles of the putative AAV-PHP.B receptor Ly6a in Npc1m1N/m1N mice. Our data suggest that robust improvements in NPC1 disease phenotypes occur even with modest CNS transduction and that improved neurotrophic capsids have the potential for superior NPC1 AAV gene therapy vectors.
- 18 August 2021
- Published by Life Science Alliance, LLC in Life Science Alliance
- Vol. 4 (10) , e202101040
Open AccessImproved systemic AAV gene therapy with a neurotrophic capsid in Niemann–Pick disease type C1 mice
Niemann–Pick C1 disease (NPC1) is a rare, fatal neurodegenerative disease caused by mutations in NPC1, which encodes the lysosomal cholesterol transport protein NPC1. Disease pathology involves lysosomal accumulation of cholesterol and lipids, leading to neurological and visceral complications. Targeting the central nervous system (CNS) from systemic circulation complicates treatment of neurological diseases with gene transfer techniques. Selected and engineered capsids, for example, adeno-associated virus (AAV)-PHP.B facilitate peripheral-to-CNS transfer and hence greater CNS transduction than parental predecessors. We report that systemic delivery to Npc1m1N/m1N mice using an AAV-PHP.B vector ubiquitously expressing NPC1 led to greater disease amelioration than an otherwise identical AAV9 vector. In addition, viral copy number and biodistribution of GFP-expressing reporters showed that AAV-PHP.B achieved more efficient, albeit variable, CNS transduction than AAV9 in Npc1m1N/m1N mice. This variability was associated with segregation of two alleles of the putative AAV-PHP.B receptor Ly6a in Npc1m1N/m1N mice. Our data suggest that robust improvements in NPC1 disease phenotypes occur even with modest CNS transduction and that improved neurotrophic capsids have the potential for superior NPC1 AAV gene therapy vectors.
- Open Access
- 1 December 2019
- Published by Elsevier in Molecular Therapy - Methods & Clinical Development
- Vol. 15, 383-391
Pathogenesis of Hepatic Tumors following Gene Therapy in Murine and Canine Models of Glycogen Storage Disease
- 1 December 2019
- Published by Elsevier in Molecular Therapy - Methods & Clinical Development
- Vol. 15, 383-391
Open AccessPathogenesis of Hepatic Tumors following Gene Therapy in Murine and Canine Models of Glycogen Storage Disease
- 24 September 2019
- Published by SAGE Publications in Human Gene Therapy
- Vol. 30 (10) , 1236-1244
Gene Therapy for Methylmalonic Acidemia: Past, Present, and Future
Methylmalonic acidemia (MMA) is a severe, and sometimes lethal, monogenic metabolic disorder in need of improved treatments. A number of new genomic therapies, which include canonical adeno-associated virus gene addition, genome editing, and systemic mRNA therapy, have shown great promise in murine models of MMA. Each approach has unique advantages and disadvantages for treating genetic disorders like MMA. This article reviews traditional viral gene therapy experiments that have provided enabling proof of concept studies in animal models, and newer approaches that may emerge as effective treatments for MMA and related disorders of organic acid metabolism.
- 24 September 2019
- Published by SAGE Publications in Human Gene Therapy
- Vol. 30 (10) , 1236-1244
Gene Therapy for Methylmalonic Acidemia: Past, Present, and Future
Methylmalonic acidemia (MMA) is a severe, and sometimes lethal, monogenic metabolic disorder in need of improved treatments. A number of new genomic therapies, which include canonical adeno-associated virus gene addition, genome editing, and systemic mRNA therapy, have shown great promise in murine models of MMA. Each approach has unique advantages and disadvantages for treating genetic disorders like MMA. This article reviews traditional viral gene therapy experiments that have provided enabling proof of concept studies in animal models, and newer approaches that may emerge as effective treatments for MMA and related disorders of organic acid metabolism.